Listing Regulation

DiviTum®TKa results from SWOG study published in Clinical Cancer Research

Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.

2021-09-15T08:00:00+02:00September 15th, 2021 08:00|

DiviTum®TKa-resultat från SWOG-studien publicerade i Clinical Cancer Research

Biovica, verksamt inom cancerdiagnostik, meddelar idag att DiviTum®TKa-resultat från en analys av prover från den stora SWOG S0226-studien har publicerats i den högt rankade vetenskapliga tidskriften Clinical Cancer Research som ges ut av American Association for Cancer Research (AACR). De starka resultaten stöder användningen av DiviTum®TKa som ett verktyg för att övervaka sjukdomsprogression vid endokrin behandling hos kvinnor med hormonreceptorpositiv spridd bröstcancer.

2021-09-15T08:00:00+02:00September 15th, 2021 08:00|

Lovande DiviTumTKa-resultat från Novartis BIOITALEE-studie presenteras vid ESMO

Biovica, verksamt inom cancerdiagnostik, meddelar idag att DiviTumTKa-resultat från den stora Novartis BIOITALEE-studien kommer att presenteras som en poster på konferensen European Society for Medical Oncology (ESMO) 16–21 september 2021. Resultaten stärker DiviTumTKas potential som verktyg för monitorering av behandling med CDK4/6-hämmare.

2021-09-14T08:00:00+02:00September 14th, 2021 08:00|

Promising DiviTumTKa results from BioItaLEE study presented at ESMO

Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum®TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.

2021-09-14T08:00:00+02:00September 14th, 2021 08:00|

Announcement from Biovica International’s annual general meeting

The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 31 August 2021 and the following resolutions were passed by the meeting.

2021-08-31T11:20:00+02:00August 31st, 2021 11:20|

Kommuniké från årsstämma i Biovica International

Årsstämman i Biovica International AB ("Biovica" eller "Bolaget") hölls idag den 31 augusti 2021 varvid aktieägarna fattade följande beslut.

2021-08-31T11:20:00+02:00August 31st, 2021 11:20|

CEO’s presentation ahead of the 2021 Annual General Meeting has been published

Biovica, active in cancer diagnostics, today announced that a pre-recorded presentation with CEO Anders Rylander has been published.

2021-08-27T14:30:00+02:00August 27th, 2021 14:30|

VDs anförande inför årsstämman 2021 har publicerats

Biovica, verksamt inom cancerdiagnostik, meddelar idag att ett förinspelat anförande med vd Anders Rylander har publicerats.

2021-08-27T14:30:00+02:00August 27th, 2021 14:30|

Biovica strengthens management team

Biovica, active in cancer diagnostics, today announced that Warren Cresswell has been appointed President Americas and will be part of the management team.

2021-08-10T08:00:00+02:00August 10th, 2021 08:00|

Biovica förstärker ledningsgruppen

Biovica, verksamt inom cancerdiagnostik, meddelar idag att Warren Cresswell har utsetts till President Americas och kommer att ingå i ledningsgruppen.

2021-08-10T08:00:00+02:00August 10th, 2021 08:00|